Investors are weighing high-stakes catalysts for Duchenne muscular dystrophy (DMD) stocks Capricor Therapeutics (CAPR) and Sarepta Therapeutics (SRPT). Capricor is preparing an FDA submission for its therapy and reporting earnings, with analysts expecting zero revenue. Meanwhile, Sarepta faces legal and safety pressure ahead of its results, where revenue is projected at nearly $391 million.